Chambers & Partners Guide 2015

For some years now, the Chambers & Partners Guide assesses the reputation and competence of thousands of lawyers in Europe on the basis of interviews that their investigation team carries out directly with clients and other lawyers.

This year’s Guide highlights the fact that Faus & Moliner’s has advised Uriach on the sale of its generic business, Pharmagenus, to Amneal.

The Guide describes Faus & Moliner as an “Exceptional boutique offering specialist services to clients in the pharmaceutical, biotech and medical devices industries. Frequently provides advice to public bodies on draft regulations. Actively involved in compliance projects”.

The firm’s strengths are defined by the clients themselves in their interviews. “An absolutely phenomenal team; the lawyers know an incredible amount about the market and are always up to date”, the Guide quotes one client. “An accessible team with a practical and commercial approach, able to really understand our needs as clients”, states another.

In the 2015 Edition of the Guide, three lawyers of Faus & Moliner have deserved a special mention, consolidating our firm as the leading one in the area of pharmaceutical law in Spain:

The co-founder of the firm Jordi Faus is described by his clients as “incredibly experienced, proactive and really able to put himself into clients’ shoes. He’s number one on the market”. The Guide adds that Faus regularly advises both domestic and international clients across the pharmaceutical and healthcare industries.

Xavier Moliner is described by Chambers as a highly regarded litigator with extensive experience in product liability and public procurement, and who maintains a strong reputation on the market.

Juan Suárez is praised by clients for his in-depth knowledge of the Spanish life sciences market and strength in regulatory matters. He focuses on regulation and advertising of medical devices and medicinal and special food products.

Some significant clients of the firm are also mentioned among which they name Alk-Abello, Biogen, Boehringer, Esteve and Novartis.